Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by dardanion Aug 26, 2016 10:40am
144 Views
Post# 25179973

RE:RE:RE:RE:RE:Challenges

RE:RE:RE:RE:RE:Challenges I think this board is agreed that a 700 page document that probably required a Mac truck to deliver and took 7 months by 15 full time researchers to compile isn't likely to get approved within the next few days so let's move on to the Q2 financials possibly due after hours today. I doubt Roger will put a number to the TLC-2000's sold so far but look for a headline number like a 15% or 20% increase in sales. Of course, you have to be diligent and scroll down to the bottom to see if they actually turned a profit after accounting for expenses. Hopefully this time around Roger's arithmetic skills have improved. He's been stating that their present cash burn is around $300,000 a month but he said that before the last financial report was released and the actual figure came in closer to $385,000. Cash left and burn rate will be of key interest to investors to help gauge how long they can tough it out before resorting to another PP. A lot of mouths to feed looking at their website so those people would need assurances pretty soon that their jobs are safe for at least another year. Look for a hint on that subject in the MD&A since we're so close to when it's got to get done. I realize Roger is hoping for news to boost the sp before tackling another financial instrument but his cancer procedure might end up being just too complicated and experimental for HC to rush approval.
Bullboard Posts